PE20191319A1 - Anticuerpos novedosos contra el factor xi y sus usos - Google Patents
Anticuerpos novedosos contra el factor xi y sus usosInfo
- Publication number
- PE20191319A1 PE20191319A1 PE2019000666A PE2019000666A PE20191319A1 PE 20191319 A1 PE20191319 A1 PE 20191319A1 PE 2019000666 A PE2019000666 A PE 2019000666A PE 2019000666 A PE2019000666 A PE 2019000666A PE 20191319 A1 PE20191319 A1 PE 20191319A1
- Authority
- PE
- Peru
- Prior art keywords
- sequence seq
- antibody
- heavy chain
- light chain
- antibodies against
- Prior art date
Links
- 108010074864 Factor XI Proteins 0.000 title abstract 2
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un anticuerpo monoclonal o fragmento de union a antigeno del mismo, el cual se une especificamente al Factor XI humano y/o al Factor Xl a humano, que comprende: una CDR1 de la cadena ligera que comprende la secuencia SEQ ID NO: 8; una CDR2 de la cadena ligera que comprende la secuencia SEQ ID NO: 9; una CDR3 de la cadena ligera que comprende la secuencia SEQ ID NO: 10; una CDR1 de la cadena pesada que comprende la secuencia SEQ ID NO: 11; una CDR2 de la cadena pesada que comprende la secuencia SEQ ID NO: 12; y una CDR3 de la cadena pesada que comprende la secuencia SEQ ID NO: 13. Dicho anticuerpo inhibe la trombosis sin comprometer la homeostasis, siendo util en el tratamiento de enfermados y condiciones relacionadas con trombosis. Tambien se refiere a un polinucleotido, un vector, una celula huesped que codifica dicho anticuerpo y una composicion farmaceutica que comprende dicho anticuerpo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016099474 | 2016-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191319A1 true PE20191319A1 (es) | 2019-09-24 |
Family
ID=59914459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000666A PE20191319A1 (es) | 2016-09-20 | 2017-09-18 | Anticuerpos novedosos contra el factor xi y sus usos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10654941B2 (es) |
| EP (2) | EP3515947B1 (es) |
| JP (1) | JP2019537451A (es) |
| KR (1) | KR20190075920A (es) |
| CN (1) | CN110099927A (es) |
| AR (1) | AR109683A1 (es) |
| AU (1) | AU2017329645A1 (es) |
| BR (1) | BR112019005449A2 (es) |
| CA (1) | CA3037087A1 (es) |
| DK (1) | DK3515947T3 (es) |
| ES (1) | ES2984011T3 (es) |
| FI (1) | FI3515947T3 (es) |
| IL (1) | IL265383A (es) |
| MX (1) | MX2019003077A (es) |
| PE (1) | PE20191319A1 (es) |
| RU (1) | RU2758160C2 (es) |
| TW (1) | TW201825523A (es) |
| WO (1) | WO2018054813A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| AU2017286432B2 (en) | 2016-06-14 | 2020-09-24 | Adimab, Llc | Anti-coagulation factor XI antibodies |
| JP7139332B2 (ja) | 2016-12-23 | 2022-09-20 | ノバルティス アーゲー | 第ｘｉ因子抗体および使用方法 |
| CA3184718A1 (en) * | 2020-07-02 | 2022-01-06 | Lei Wang | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| WO2022002233A1 (zh) * | 2020-07-03 | 2022-01-06 | 苏州康宁杰瑞生物科技有限公司 | 凝血因子xi(fxi)结合蛋白 |
| CN120923627A (zh) * | 2024-05-08 | 2025-11-11 | 上海交通大学医学院附属瑞金医院 | 一种具有抗凝血活性的单克隆抗体及其应用 |
| CN118359711B (zh) * | 2024-06-20 | 2024-10-15 | 华淞(上海)生物医药科技有限公司 | 一种抗脊髓灰质炎病毒1型抗体及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| KR20050059332A (ko) * | 2002-11-07 | 2005-06-17 | 이뮤노젠 아이엔씨 | 항-씨디33 항체와 이를 이용한 급성 골수성 백혈병의치료방법 |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| AU2014202009A1 (en) * | 2007-11-21 | 2014-05-01 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| LT3002298T (lt) | 2007-11-21 | 2019-12-10 | Univ Oregon Health & Science | Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai |
| TR201904662T4 (tr) * | 2008-12-18 | 2019-05-21 | Gruber Andras | Anti-fxı antikorları ve kullanma yöntemleri. |
| CA2872926C (en) * | 2012-05-10 | 2022-07-05 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| CA3025896A1 (en) * | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
| CA3010224A1 (en) * | 2016-01-22 | 2017-07-27 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
-
2017
- 2017-09-18 ES ES17769050T patent/ES2984011T3/es active Active
- 2017-09-18 RU RU2019111862A patent/RU2758160C2/ru active
- 2017-09-18 CN CN201780057947.8A patent/CN110099927A/zh active Pending
- 2017-09-18 JP JP2019536662A patent/JP2019537451A/ja active Pending
- 2017-09-18 WO PCT/EP2017/073410 patent/WO2018054813A1/en not_active Ceased
- 2017-09-18 AU AU2017329645A patent/AU2017329645A1/en not_active Abandoned
- 2017-09-18 FI FIEP17769050.0T patent/FI3515947T3/fi active
- 2017-09-18 EP EP17769050.0A patent/EP3515947B1/en active Active
- 2017-09-18 DK DK17769050.0T patent/DK3515947T3/da active
- 2017-09-18 KR KR1020197011122A patent/KR20190075920A/ko not_active Withdrawn
- 2017-09-18 PE PE2019000666A patent/PE20191319A1/es unknown
- 2017-09-18 EP EP24166025.7A patent/EP4413996A3/en active Pending
- 2017-09-18 US US16/335,133 patent/US10654941B2/en active Active
- 2017-09-18 CA CA3037087A patent/CA3037087A1/en active Pending
- 2017-09-18 MX MX2019003077A patent/MX2019003077A/es unknown
- 2017-09-18 BR BR112019005449A patent/BR112019005449A2/pt not_active IP Right Cessation
- 2017-09-19 TW TW106132100A patent/TW201825523A/zh unknown
- 2017-09-20 AR ARP170102598A patent/AR109683A1/es unknown
-
2019
- 2019-03-14 IL IL265383A patent/IL265383A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR109683A1 (es) | 2019-01-09 |
| TW201825523A (zh) | 2018-07-16 |
| MX2019003077A (es) | 2020-02-05 |
| CN110099927A (zh) | 2019-08-06 |
| FI3515947T3 (fi) | 2024-07-24 |
| AU2017329645A8 (en) | 2019-05-02 |
| RU2758160C2 (ru) | 2021-10-26 |
| EP3515947A1 (en) | 2019-07-31 |
| WO2018054813A1 (en) | 2018-03-29 |
| ES2984011T3 (es) | 2024-10-28 |
| RU2019111862A (ru) | 2020-10-22 |
| EP4413996A2 (en) | 2024-08-14 |
| EP4413996A3 (en) | 2024-10-23 |
| DK3515947T3 (da) | 2024-07-29 |
| CA3037087A1 (en) | 2018-03-29 |
| JP2019537451A (ja) | 2019-12-26 |
| AU2017329645A1 (en) | 2019-04-04 |
| US20190225705A1 (en) | 2019-07-25 |
| RU2019111862A3 (es) | 2021-01-12 |
| KR20190075920A (ko) | 2019-07-01 |
| EP3515947B1 (en) | 2024-05-29 |
| IL265383A (en) | 2019-05-30 |
| BR112019005449A2 (pt) | 2019-10-01 |
| US10654941B2 (en) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| PE20191319A1 (es) | Anticuerpos novedosos contra el factor xi y sus usos | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20170943A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20180926A1 (es) | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
| ECSP17012781A (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos |